Phase
Condition
Hepatitis B
Hepatitis
Liver Disorders
Treatment
Placebo
ABI-4334
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Body mass index (BMI) ≥ 18.0 and < 35.0 kg/m(2), where BMI = weight (kg)/(height [m])(2) with a minimum body weight of 45 kg
Chronic hepatitis B infection, defined as HBV infection for ≥ 6 months documented
Treatment-naïve or off-antiviral therapy for ≥ 24 weeks prior to Screening
Lack of bridging fibrosis or cirrhosis
Exclusion
Exclusion Criteria:
Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV),hepatitis D virus (HDV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV)
History of liver transplant or evidence of advanced liver disease, cirrhosis, orhepatic decompensation
Clinically significant diseases or conditions
History of hepatocellular carcinoma
Study Design
Connect with a study center
ARENSIA Exploratory Medicine Cluj-Napoca
Sofia,
BulgariaSite Not Available
ARENSIA Exploratory Medicine Chisinau
Chisinau,
Moldova, Republic ofActive - Recruiting
New Zealand Clinical Research
Auckland,
New ZealandActive - Recruiting
ARENSIA Exploratory Medicine S.R.L.
Bucharest,
RomaniaSite Not Available
ARENSIA Exploratory Medicine SRL
Cluj-Napoca,
RomaniaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.